Missed GME or NVDA? Donโt Miss the Next One.โ
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities โ for free.
Home โบ Stocks โบ Surgery Partners Inc. (SGRY) Stock Forecast & Price Prediction United States | NASDAQ | Healthcare | Medical Care Facilities
$20.33
-2.84 (-12.26%)Did SGRY Make This Month's Elite Buy List?
We don't follow just any analyst โ only the top 3% with a proven track record make our cut. See if Surgery Partners is one of their latest high-conviction picks.
Based on our analysis of 19 Wall Street analysts, SGRY has a bullish consensus with a median price target of $33.00 (ranging from $24.00 to $36.00). The overall analyst rating is Strong Buy (8.8/10). Currently trading at $20.33, the median forecast implies a 62.3% upside. This outlook is supported by 9 Buy, 3 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Jason Cassorla at Citigroup, projecting a 77.1% upside. Conversely, the most conservative target is provided by Andrew Mok at Barclays, suggesting a 18.1% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
These are the latest 20 analyst ratings and price targets for SGRY.
Date | Firm | Analyst | Rating | Change | Price Target |
---|---|---|---|---|---|
May 27, 2025 | Barclays | Andrew Mok | Equal-Weight | Maintains | $24.00 |
Apr 21, 2025 | Benchmark | Bill Sutherland | Buy | Reiterates | $35.00 |
Mar 25, 2025 | RBC Capital | Ben Hendrix | Outperform | Reiterates | $35.00 |
Mar 11, 2025 | Macquarie | Tao Qiu | Outperform | Maintains | $33.00 |
Dec 3, 2024 | JP Morgan | Lisa Gill | Neutral | Maintains | $28.00 |
Nov 20, 2024 | RBC Capital | Ben Hendrix | Outperform | Maintains | $35.00 |
Nov 19, 2024 | Macquarie | Tao Qiu | Outperform | Maintains | $34.00 |
Nov 13, 2024 | Macquarie | Tao Qiu | Outperform | Maintains | $34.00 |
Nov 4, 2024 | Macquarie | Tao Qiu | Outperform | Maintains | $35.00 |
Oct 14, 2024 | UBS | A.J. Rice | Buy | Initiates | $38.00 |
Oct 11, 2024 | Keybanc | Matthew Gillmor | Sector Weight | Initiates | $0.00 |
Oct 4, 2024 | Cantor Fitzgerald | Sarah James | Overweight | Reiterates | $43.00 |
Aug 26, 2024 | Benchmark | Bill Sutherland | Buy | Reiterates | $50.00 |
Aug 20, 2024 | Cantor Fitzgerald | Sarah James | Overweight | Reiterates | $43.00 |
Aug 19, 2024 | Cantor Fitzgerald | Sarah James | Overweight | Reiterates | $43.00 |
Aug 7, 2024 | Citigroup | Jason Cassorla | Buy | Maintains | $36.00 |
Aug 7, 2024 | RBC Capital | Ben Hendrix | Outperform | Reiterates | $49.00 |
Aug 7, 2024 | Benchmark | Bill Sutherland | Buy | Reiterates | $50.00 |
Jul 10, 2024 | Cantor Fitzgerald | Sarah James | Overweight | Reiterates | $43.00 |
Jul 9, 2024 | Cantor Fitzgerald | Sarah James | Overweight | Reiterates | $43.00 |
The following stocks are similar to Surgery Partners based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Surgery Partners Inc. has a market capitalization of $2.61B with a P/E ratio of 2,956.0x. The company generates $3.17B in trailing twelve-month revenue with a -6.1% profit margin.
Revenue growth is +8.2% quarter-over-quarter, while maintaining an operating margin of +11.5% and return on equity of -0.3%.
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings โ tracked and updated every Monday and Thursday.
Provides surgical services through outpatient facilities.
The company operates a network of ambulatory surgical centers, hospitals, and physician practices, focusing on outpatient surgical procedures. It generates revenue by delivering high-quality surgical care and leveraging partnerships with healthcare practitioners to enhance service offerings.
Surgery Partners Inc. is positioned in the growing outpatient care sector, which is increasingly preferred for its cost-effectiveness and specialized care. The company's emphasis on advanced medical technologies and broad surgical disciplines ensures it meets evolving healthcare demands while maintaining a strong market presence.
Healthcare
Medical Care Facilities
15,000
Mr. J. Eric Evans
United States
2015
Surgery Partners, Inc. will hold its Q1 2025 Earnings Conference Call on May 12, 2025, at 8:30 AM ET, featuring CEO Eric Evans and CFO David Doherty.
The upcoming earnings call for Surgery Partners provides crucial insights into the company's financial health and future outlook, influencing stock performance and investor sentiment.
Surgery Partners, Inc. (NASDAQ: SGRY) announced its first-quarter results for 2025, ending March 31. Further financial details are pending release.
Surgery Partners' Q1 results may impact stock performance and investor sentiment, indicating operational efficiency and potential growth in the competitive healthcare sector.
Surgery Partners (SGRY) reported Q3 earnings of $0.04 per share, missing the Zacks estimate of $0.08 and down from $0.10 per share year-over-year.
Surgery Partners' earnings miss signals potential operational challenges, which may lead to decreased investor confidence and impact stock performance negatively.
Advanced Aesthetics Plastic Surgery has partnered with Ascend Aesthetic Partners, adding three new physicians and expanding to 24 doctors across six states to enhance aesthetic medicine collaboration.
The partnership enhances Ascend Aesthetic Partners' market presence and expertise, potentially increasing revenue and attracting investors focused on the growing aesthetic medicine sector.
Surgery Partners, Inc. (NASDAQ:SGRY) will release Q1 2025 results on May 12, 2025, before market opens, followed by a conference call at 8:30 a.m. ET.
The scheduled earnings release and conference call will provide insights into Surgery Partners' financial health and operational performance, influencing investor sentiment and stock price.
Surgery Partners, Inc. (NASDAQ:SGRY) will hold its Q4 2024 earnings conference call on March 3, 2025, at 8:30 AM ET, featuring key executives and analysts from major financial firms.
The upcoming earnings call for Surgery Partners could reveal key financial metrics and strategic insights, impacting stock performance and investor sentiment.
Based on our analysis of 19 Wall Street analysts, Surgery Partners Inc. (SGRY) has a median price target of $33.00. The highest price target is $36.00 and the lowest is $24.00.
According to current analyst ratings, SGRY has 9 Buy ratings, 3 Hold ratings, and 0 Sell ratings. The stock is currently trading at $20.33. Always conduct your own research and consider your investment goals before making investment decisions.
Wall Street analysts predict SGRY stock could reach $33.00 in the next 12 months. This represents a 62.3% increase from the current price of $20.33. Please note that this is a projection by Wall Street analysts and not a guarantee.
The company operates a network of ambulatory surgical centers, hospitals, and physician practices, focusing on outpatient surgical procedures. It generates revenue by delivering high-quality surgical care and leveraging partnerships with healthcare practitioners to enhance service offerings.
The highest price target for SGRY is $36.00 from Jason Cassorla at Citigroup, which represents a 77.1% increase from the current price of $20.33.
The lowest price target for SGRY is $24.00 from Andrew Mok at Barclays, which represents a 18.1% increase from the current price of $20.33.
The overall analyst consensus for SGRY is bullish. Out of 19 Wall Street analysts, 9 rate it as Buy, 3 as Hold, and 0 as Sell, with a median price target of $33.00.
Stock price projections, including those for Surgery Partners Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.